Skip to content

Canceled by the investigator Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19)

Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19)

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030522
Enrollment
Unknown
Registered
2020-03-06
Start date
2020-03-09
Completion date
Unknown
Last updated
2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Laboratory confirmed infection with 2019-nCoV; 2. Clinical classification is mild or common; 3. Lung involvement confirmed with chest imaging; 4. Hospitalised with: Fever: axilla temperature >= 36.7 degrees C, or Oral temperature >= 38.0 degrees C, or rectal temperature >= 38.6 degrees C.And at least one of Respiratory rate > 24/min Or Cough; 5. TCM syndrome differentiation is phlegm-heat obstructing the lung syndrome; 6. Must agree not to enroll in another study of an investigational agent prior to completion of Day 28 of study; 7. Aged between 18-75 years of signing Informed Consent Form.

Exclusion criteria

Exclusion criteria: 1. Patients with serious primary diseases such as severe mental and psychological disorders, heart and brain vessels diseases, liver and kidney diseases, endocrine diseases, hematopoietic system diseases and malignant tumors; 2. Patients are known to be allergic to trail drugs or a certain Chinese medicine of this study; 3. Women are breastfeeding, pregnant or preparing for pregnancy; 4. Patients participating in other clinical studies.

Design outcomes

Primary

MeasureTime frame
Time to Clinical Recovery (TTCR);

Secondary

MeasureTime frame
Time for temperature to return to normal;Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen;The rate of progression from mild/moderate type to heavy/critical type;4. Laboratory tests(white blood cell and lymphocyte count, erythrocyte sedimentation rate, C-reactive protein);chest CT;Chinese medicine symptom complex score;

Countries

China

Contacts

Public ContactChuantao Zhang

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

1035788783@qq.com+86 13880336152

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026